Table 2.
Type of Nano-System | Name of Nano-System | Drug Formulated | Testing Phase |
---|---|---|---|
Polymer-drug | Poly(ethylene glycol)-P(HEMASN38) | SN3S | Preclinical: in vivo |
Poly (TPGS)-PEG-GEM | Gemcitabine | Preclinical: in vitro | |
Methacrylate-based GEM-monomer conjugate 3 | Gemcitabine | Preclinical: in vitro | |
Poly (ethylene glycol)-block-poly (2 methyl-2- carboxyl-propylene carbonate)-graft-dodecanol-graft-cationic ligand | Gemcitabine | Preclinical: in vivo | |
Block copolymer | Styrene-maleic acid | CDF | Preclinical: in vivo |
Poly(ethylene glycol)-b-poly(glutamic acid) | Oxaliplatin | Preclinical: in vivo | |
Mixed micelles | Poly(vinyl pyrrolidone-b-polycaprolactone) (PVP- b-PCL) and poly(vinyl pyrrolidone-b- poly(dioxanone-co-methyl dioxanone)) (PVP-b- P(DX-co-MeDX) | Gemcitabine, doxorubicin. Doxorubicin hydrochloride. 5- fluorouracil paclitaxel | Preclinical: in vitro |
Graft polymer | Poly(allylamine)-g-cholesterol | BNIPDAoct | Preclinical: in vivo |
Dendrimer | PAMAM-hyaluronic acid | CDF | Preclinical: in vitro |
Poly(ethylene glycol)-PMAM-poly(ethylene glycol)-Flt-2 | Gemcitabine Hydrochloride | Preclinical: in vitro | |
Thermo-responsive polymer | Poly(diEGMAco-OEGMA300)-b-PEHMA | Squalenoyl-gemcitabine | Preclinical: in vitro |
pH-responsive polymer | Poly(styrene-alt-maleic anhydride) | Curcumin | Preclinical: in vitro |
Ultrasound-responsive nano-emulsion | PEG-PLLA | Paclitaxel | Preclinical: In vivo |
Albumin | Abraxane® | Paclitaxel | FDA approved 2013 |
Abraxane®/Gemcitabine | Paclitaxel & gemcitabine | Phase III | |
Inorganic nanoparticle | Iron oxide-dextran-DOX | Doxorubicin | Preclinical: in vitro |
Iron oxide-antiCD47-GEM | Gemcitabine | Preclinical: in vitro | |
Iron oxide-gold | BNIPDSpm | Preclinical: in vivo | |
Iron oxide-gold-GEM | Gemcitabine | Preclinical: in vivo |
Notes: Reprinted with permission from Manzur A, Oluwasanmi A, Moss D, Curtis A, Hoskins C. Nanotechnologies in pancreatic cancer therapy. Pharmaceutics. 2017;9(4):39.76